Patients with chronic granulocytic leukemia (CML) who should be selected for hematopoietic stem cell transplantation in the era of Gleevec (imatinib) are as follows: 1. Pediatric patients with chronic granulocytic leukemia, whether in the chronic phase, accelerated or acute phase, are preferred for hematopoietic stem cell transplantation; 2. Patients with chronic granulocytic leukemia in the accelerated and acute phases, but patients in the accelerated phase should be cautious; 3. Patients with CML who are in the chronic phase but have mutations at the T315I locus should be selected first for hematopoietic stem cell transplantation; 4. Patients with CML who are intolerant or resistant to imatinib.